iRadimed Raised Its Quarterly Dividend To $0.20/Share From $0.17/Share

IRADIMED CORPORATION (the "Company" or "Iradimed") (NASDAQ:IRMD) announced today its financial results for the quarter and year ended December 31, 2025. The Company is a leader in developing innovative magnetic resonance imaging ("MRI") compatible medical devices and products. The Company is a provider of (i) non-magnetic intravenous ("IV") infusion pump systems and (ii) non-magnetic patient vital signs monitoring systems that are each designed for use during MRI procedures.

"We are thrilled to report our eighteenth consecutive quarter of record revenue, achieving $22.7 million in the fourth quarter of 2025—a 17% increase year-over-year and exceeding our previously announced guidance. We successfully shipped the initial 3870 units in the fourth quarter of 2025 as planned, marking a key milestone in our product roadmap. The full rollout of the next-generation 3870 MRI-compatible IV infusion pump is expected to begin in the first quarter of 2026, with real acceleration and meaningful revenue contribution expected in the second half of the year. These accomplishments were made possible by the exceptional dedication and hard work of our employees, who tirelessly worked to clear the FDA 510k requirements and seamlessly navigated the transition to our new Orlando facility earlier in 2025, while maintaining operational excellence and supporting this important launch. We are deeply grateful for their commitment and contributions to our continued success.

"We remain focused on innovation, operational efficiency, and delivering strong returns to stockholders—including our decision to increase our regular quarterly cash dividend to $0.20 per share from $0.17 per share, reflecting our confidence in the business outlook," said Roger Susi, President and Chief Executive Officer of Iradimed.